B
BPMC
Blueprint Medicines Corp
This stock has been delisted.
News
Press Releases
Financial Reports
Profile
Benzinga·07/22/2025 18:09
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
TipRanks·07/18/2025 10:32
Cogent Biosciences price target raised to $22 from $15 at Citi
TipRanks·07/18/2025 10:29
Blueprint Medicines Completes $9.1B Merger, Delists from Nasdaq
Reuters·07/18/2025 10:10
Sanofi to Acquire Blueprint Medicines Corporation Following Successful Tender Offer Completion
Reuters·07/18/2025 10:04
Sanofi Finalizes Acquisition of Blueprint Medicines, Expanding Immunology Portfolio
Reuters·07/17/2025 05:03
BRIEF-Sanofi Announces Extension Of Blueprint Tender Offer
Reuters·07/17/2025 05:00
Rothko Merger Sub, Inc., a Sanofi Subsidiary, Extends Tender Offer for Blueprint Medicines
Benzinga·07/14/2025 19:01
What's Driving the Market Sentiment Around Blueprint Medicines?
TipRanks·07/09/2025 02:01
Top Executives at Blueprint Medicines Make Significant Stock Sales!
Reuters·07/08/2025 20:20
Christina Rossi, COO, Reports Disposal of Common Shares in Blueprint Medicines Corporation
Benzinga·07/08/2025 18:26
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
NASDAQ·07/08/2025 14:01
BPMC Quantitative Stock Analysis
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.